PTK2 (PTK2 protein tyrosine kinase 2) by Schwock, J & Dhani, N









Atlas Genet Cytogenet Oncol Haematol. 2010; 14(10)   854 
Atlas of Genetics and Cytogenetics 
in Oncology and Haematology 
OPEN ACCESS JOURNAL AT INIST-CNRS 
PTK2 (PTK2 protein tyrosine kinase 2) 
Joerg Schwock, Neesha Dhani 
Department of Laboratory Medicine and Pathobiology, Division of Anatomical Pathology, University of 
Toronto, 1 King's College Circle, 6th Floor, Toront, Ontario M5S 1A8, Canada (JS); University Health 
Network, Princess Margaret Hospital, Division of Medical Oncology and Hematology and Institute of 
Medical Sciences, University of Toronto, Princess Margaret Hospital/Ontario Cancer Institute, 610 
University Ave., Room: 7-113, Toronto, Ontario M5G 2M9, Canada (ND) 
 
Published in Atlas Database: March 2011 
Online updated version : http://AtlasGeneticsOncology.org/Genes/PTK2ID41898ch8q24.html 
DOI: 10.4267/2042/46033 
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence. 
© 2011 Atlas of Genetics and Cytogenetics in Oncology and Haematology 
 
Identity 
Other names: FADK; FAK; FAK1; FRNK; 
pp125FAK 




Cloning of the FAK cDNA and initial characterization 
of the kinase was accomplished independently by three 
groups in 1992 (Schaller et al., 1992; Hanks et al., 
1992; Guan and Shalloway 1992). The cDNA of the 
human FAK homologue was first cloned by André and 
Becker-André (1993). The position of the human PTK2 
gene encoding FAK on chromosome 8 was first 
predicted by Fiedorek and Kay (1995). 
Transcription 
Initial expression studies using reverse transcriptase 
PCR detected FAK mRNA in a series of lymphoid cell 
lines as well as HeLa and SK-N-SH neuroblastoma 
cells indicating ubiquitous expression. Only a 
lymphocyte adhesion deficient cell line tested negative 
for the FAK transcript (André and Becker-André 
1993). Transcripts of different sizes were detected in 
different human tissues in the same study with 
differential expression patterns for these transcripts 
noted in brain, lung, heart, liver and placenta. 
Several transcript variants encoding different FAK 
isoforms have been found for the PTK2 gene. The full-
length nature of the following three has been 
determined. (Sources: http://useast.ensembl.org/ 
index.html; http://www.ncbi.nlm.nih.gov/pubmed/) 
- Variant 1 differs in the 5' UTR and coding sequence 
compared to variant 2. The resulting isoform (a) is 
shorter at the N-terminus compared to isoform (b). 
4414 bp - 33 exons - 1065 aa. Ave. residue weight: 
113.521. Charge: 3.5. Isoelectric point: 6.7311. 
Molecular weight: 120899.54. Number of residues: 
1065. 
- Variant 2 encodes the longest isoform (b). 4286 bp - 
31 exons - 1073 aa. Ave. residue weight: 113.366. 
Charge: 2.0. Isoelectric point: 6.6317. Molecular 
weight: 121641.45. Number of residues: 1073. 
- Variant 3 differs in the 5' UTR and coding sequence, 
and contains two additional in-frame segments near the 
3' end of the coding sequence, compared to variant 2. 
The resulting isoform (c) is shorter at the N-terminus 
and contains two additional segments in the C-terminus 
compared to isoform b. 
Protein 
Note 
Focal adhesion kinase (FAK) is a cytoplasmic non-
receptor protein tyrosine kinase which was isolated for 
the first time by co-immunoprecipitation of tyrosine-
phosphorylated proteins from cells transformed with 
Rous sarcoma virus v-Src (Kanner et al., 1990). 
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Figure 1: Schematic of focal adhesion kinase domain structure with phosphorylation sites. 
 
Description 
FAK is a ubiquitously expressed protein composed of a
N-terminal FERM domain (protein 4.1, ezrin, radixin, 
moesin), a kinase domain, three intervening proline-
rich regions (PRR) and a C-terminal focal adhesion 




Cytoplasmic and nuclear. 
Function 
FAK is characterized by a functional duality, serving as 
a kinase as well as a molecular scaffold. These two 
functions may be required independently or in concert 
depending on the context in which FAK-mediated 
signaling occurs (Sieg et al., 1999; Sieg et al., 2000). 
FAK regulates the dynamic of focal adhesion 
complexes which are sites of attachment between cells
and extracellular matrix. Cyclic assembly and 
disassembly of these complexes at the leading and 
trailing edge of the cell is required for the migration of 
mesenchymal cells and those that adopt mesenchymal-
like characteristics as a consequence of developmental 
processes or during disease states. The latter mainly 
encompasses forms of tissue repair (i.e. wound healing 
and fibrosis) as well as neoplasia (i.e. tumor invasion 
and metastasis). As an example, Figure 2 shows 
immunohistochemical staining for FAK in metastatic 
cancer of the uterine cervix. FAK has been implicated 
with the establishment of a front-back polarity 
(Tilghman et al., 2005), lamellipodial persistence at the 
leading edge (Owen et al., 2007) and release of 
adhesions at the trailing edge (Iwanicki et al., 2008). 
Integrin engagement with the extracellular matrix 
results in integrin clustering and a sequence of inter- 
and intramolecular events that permit the 
autophosphorylation of FAK at Tyr397 (Dunty et al., 
2004). Subsequent recruitment of Src-family kinases 
through SH2-domain binding is followed by a mutual 
activation of both kinases. In the case of FAK this 
further activation is accomplished by phosphorylation 
of other tyrosine residues, specifically Tyr407, 576, 
577, 861 and 925. Phosphorylation of Tyr576 and 577 
increases FAK kinase activity whereas the remaining 
tyrosine residues serve as docking sites for SH2-
containing factors such as Grb2 which links FAK into 
the MAPK pathway. Tyr397 also constitutes a docking 
site for the p85 subunit of PI3K (Chen and Guan, 1994) 
and phospholipase C gamma (Zhang et al., 1999). The 
PRRs are sites of interaction with SH3-containing 
factors which transmit signals downstream of the 
kinase and regulate the activity of Rho-family GTPases 
in charge of cell motility through the formation of 
stress fibres (RhoA), lamellipodia (Rac) and filopodia 
(Cdc42). Crk-associated substrate (p130Cas), initially 
identified in a two-hybrid screen, is one of the main 
downstream factors that bind to the PRRs of FAK 
(Polte and Hanks, 1995). Signaling via p130Cas 
towards Crk, DOCK180 and Rac has been linked to 
membrane ruffling, lamellipodia formation and cell 
motility (Harte et al., 1996; Cho and Klemke, 2002). A 
second essential downstream target of FAK is paxillin 
(Bellis et al., 1995), an adaptor protein lacking itrinsic 
kinase activity which can be phosphorylated at two 
sites, Tyr31 and Tyr118, and binds FAK within the C-
terminal focal adhesion targeting (FAT) region 
(Hayashi et al., 2002). Mutations in FAK that disrupt 
binding to paxillin affect the localization of the kinase 
to focal contacts. Paxillin may also be involved in 
regulation of MAPK downstream signaling due to an 
overlapping binding site with Grb2 which binds to 
Tyr925 within the FAT region (Liu et al., 2002). 
More recent studies link FAK to the regulation of cell-
cell contacts, microtubule stability and control of gene 
transcription. Conflicting results have been reported 
from different experimental systems implicating FAK 
either with the dissolution (Avizienyte et al., 2002; 
Cicchini et al., 2008) or the promotion (Yano et al., 
2004; Playford et al., 2008) of cell-cell contacts which 
suggests a dependency of this feature on the specific 
cellular context. Ezratty et al. (2005) reported on the 
role of FAK, Grb2 and dynamin in microtubule-
induced focal adhesion disassembly. Earlier studies 
demonstrated an integrin-mediated activation of FAK 
at the leading edge of migrating cells as requirement 
for microtubule stabilization mediated by Rho and 
mDia (Palazzo et al., 2004). This mechanism also 
involves localization of a lipid raft marker, ganglioside 
GM1, to the leading edge. Xie et al. (2003) showed that
Cdk5-mediated serine-phosphorylation of FAK was 
linked to the localization of the kinase at microtubule 
fork structures which contribute to nuclear 
repositioning in migrating neuronal cells. Recently, 
serine-phosphorylated FAK was shown to co-localize 
with centrosomes in mitotic endothelial cells. In this 
study by Park et al. (2009), FAK was also found  
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Figure 2: Immunohistochemical staining of FAK in invasive cancer of the uterine cervix. (Note the accentuation of the FAK staining 
at the margin of the tumor nests. Size bar, 1 mm). Method and antibody: Schwock et al., 2009. 
 
associated with cytoplasmic dynein, and deletion of 
FAK resulted in mitotic defects. In 2005, 
Golubovskaya et al. reported results indicating a 
physical interaction between the N-terminal fragment 
of FAK and the N-terminal transactivation domain of 
p53. This interaction led to suppression of p53-
mediated apoptosis and inhibition of the transcriptional 
activity of p53. Lim et al. (2008) subsequently provided 
data demonstrating a scaffolding role of nuclear FAK 
for MDM2-mediated p53 degradation mediated by the 
different lobes of the FERM domain. Also, basic 
sequences in the F2 lobe of the FERM domain were 
implicated in the nuclear localization of FAK (Lim et
al., 2008), but alternative mechanisms independent 
from this putative nuclear localization signal are 
thought to exist (Schaller, 2010). Another nuclear 
function was recently uncovered by Luo et al. (2009) 
who described a role of FAK in chromatin remodelling 
via its interaction with MBD2 leading to increased 
myogenin expression and muscle-terminal 
differentiation. Liu et al. (2004), Li et al. (2004) and 
Ren et al. (2004) reported an involvement of FAK in 
netrin-1 signaling downstream of the netrin receptor 
DCC with consequences for axonal outgrowth and 
guidance in the developing brain. 
- Mouse Models 
Several mouse models have been generated to elucidate 
the functions of FAK both during normal development 
and neoplasia. A role of FAK in embryonal 
development was first observed in fak-/- mice which 
displayed defects in mesoderm development and 
anterior-posterior axis formation with embryonic 
lethality around day E8.5 (Ilic et al., 1995). 
A conditional knockout model using a Cre-loxP system 
with Cre recombinase under the control of the nkx2-5 
promoter was generated by Hakim et al. (2007). The 
major abnormality reported from this study was a 
profound disturbance of the development of the cardiac 
outflow tract. Knockout mice from this study died 
shortly after birth and displayed a range of cardiac 
defects which resemble the human congenital heart 
defects Tetralogy of Fallot and persistent truncus 
arteriosus. Peng et al. (2006) and DiMichele et al. 
(2006) reported results obtained with conditional 
knockout mice which carried Cre-recombinase under 
the control of the myosin light chain 2v promoter. Peng 
et al. (2006) found that knockout mice developed 
eccentric cardiac hypertrophy upon stimulation with 
angiotensin II or pressure overload. In contrast, the
results by DiMichele et al. (2006) suggest that FAK 
functions to promote cardiac hypertrophy. In a later 
study by Peng at al. (2008) with myosin light chain-2a 
Cre mice they observed cardiac developmental 
abnormalities with thin ventricular walls and 
ventricular septal defects in the knockout mice, the
majority of which died in the embryonic stage. 
Endothelial cell-specific knockout of FAK, again using 
a Cre-loxP approach, has been reported by Shen et al. 
(2005) and Braren et al. (2006). The observed 
phenotypes in knockout mice from both studies 
strongly suggest a role of FAK in vascular 
morphogenesis, particularly vascular remodelling and 
sprouting angiogenesis. The roles of FAK in the 
cardiovascular system were reviewed by Vadali et al. 
(2007). 
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Figure 3: Schematic of the Cellular Functions of FAK. 
 
A series of mouse models suggest an essential role of 
FAK during the development of the central nervous 
system. Beggs et al. (2003) created dorsal forebrain-
specific conditional knockout mice using the Cre/loxP 
approach and observed an essential function of FAK 
for the formation of a normal basal lamina at the 
interface between radial glial end-feet and meningeal 
fibroblasts. They noted that the cortical changes seen in 
their study resembled lissencephaly phenotypes seen in 
some forms of human congenital muscular dystrophy. 
Van Miltenburg et al. (2009) investigated the role f 
FAK in normal mammary gland using a conditional 
FAK-knockout mammary epithelial cell transplantation 
model based on FAK(lox/lox)/Rosa26Cre-ERT2 donor 
mice with loss of FAK in all mammary cells. They 
observed an abnormal mammary duct development 
with a disruption of myoepithelial and luminal 
epithelial cell layer and aberrant ductal morphogenesis 
during pregnancy. 
Comprehensive reviews focused on the cellular 
functions of FAK have been published by Mitra et al. 
(2005) and Schaller (2010). Figure 3 schematically 
summarizes some of the diverse cellular functions of 
FAK. 
- Regulation 
The level of FAK expression is negatively and 
positively regulated by several transcription factors 
including p53, NF-kB and N-Myc (Golubovskaya et 
al., 2004; Beierle et al., 2007). Aside from the tyrosine 
residues implicated with FAK activation, at least four 
different serine phosphorylation sites (Ser722, 840, 8 3 
and 910) have been recognized within FAK. Although 
the function of these serine sites has been examined 
less comprehensively, their phosphorylation has 
generally been associated with FAK inactivation, such 
as during mitosis (Ma et al., 2001), in suspension and
under conditions that disturb the integrity of the actin 
cytoskeleton (Jacamo et al., 2007). FAK signaling is 
subject to additional levels of regulation which involve 
proteolytic cleavage (Dourdin et al., 2001), 
sumoylation (Kadaré et al., 2003), inhibition by FAK 
family interacting protein of 200 kDa (FIP200) (Abbi et 
al., 2002), dephosphorylation by protein-tyrosine 
phosphatases (Zeng et al., 2003), and generation of 
alternatively spliced isoforms such as FAK-related non-
kinase (FRNK) (Schaller et al., 1993). 
- Other protein family members: Pyk2. 
Homology 
% Identity for : Homo sapiens 
PTK2 
Protein DNA 
vs. Pan troglodytes PTK2 99.8 99.7 
vs. Canis lupus familiaris PTK2 97.0 91.7  
vs. Mus musculus Ptk2 97.2 90.7 
vs. Rattus norvegicus Ptk2 97.0 90.8 
vs. Gallus gallus PTK2 94.9  83.9 
vs. Danio rerio ptk2.1 83.2 74.2 
vs. Drosophila melanogaster 
Fak56D 
42.9 48.9  




(Source : http://www.ncbi.nlm.nih.gov/pubmed/) 










Increased expression of FAK was first noticed in high-
grade and metastatic sarcomas (Weiner et al., 1994) 
and later in pre-invasive as well as invasive epithelial 
neoplasms (Owens et al., 1995). In general, lower 
levels of FAK expression are found in normal tissues 
whereas the higher levels are present in metastatic 
cancer suggesting an involvement of the kinase in 
oncogenesis. In neoplastic conditions the kinase has 
been credited with a range of functions including tumor 
cell motility (Sieg et al., 1999), matrix degradation 
leading to distant spread (Hauck et al., 2002), 
suppression of apoptosis (Sonoda et al., 2000), anoikis 
(Frisch et al., 1996) and senescence (Pylayeva et al., 
2009) as well as positive effects on angiogenesis (M tra 
et al., 2006), vasculogenic mimicry (Hess et al., 2005) 
and hypoxia response (Skuli et al., 2009). Results from 
a Cre/loxP-mediated FAK-knockout model specific to 
mouse mammary epithelial cells revealed a reduced 
pool of cancer stem/progenitor cells after FAK deletion 
which suggests that the kinase may not only support 
tumor cell dissemination to distant sites, but also the 
colonization of the target organ and establishment of a
new tumor mass (Luo et al., 2009). Other transgenic 
mouse models focused on the role of FAK in neoplasia 
have been reported by McLean et al. (2004) for skin 
and by Lahlou et al. (2007), Provenzano et al. (2008) 
and Pylayeva et al. (2009) for mammary tumor 
formation and progression. 
Nervous system 
Note 
The role of FAK in glioma tumor progression and in 
the regulation of the permeability of tumor-associated 
vasculature has been described, as well as the 
therapeutic efficacy of FAK inhibition by both 
pharmacologic compounds and liposomal-mediated 
RNA interference (Shi et al., 2007; Lipinski et al., 
2008; Lee et al., 2010; Wang et al., 2011). 
Immunohistochemical analysis of 96 patient biopsies 
demonstrated higher levels of total and phosphorylated 
FAK in high grade tumors which correlated with 
inferior patient survival (Ding et al., 2010). 
Beierle et al. (2007) reported on the relevance of FAK 
as cellular survival factor in N-myc-amplified 
neuroblastoma and identified N-myc binding sites in 
the FAK promoter. Recently, the same group also 
provided data indicating greater in vivo-therapeutic 
efficacy of pharmacologic FAK inhibition in N-myc-
positive model systems (Beierle et al., 2010a; Beierle t 
al., 2010b). Efficacy of a novel small molecule dual 
IGF1R/FAK tyrosine kinase inhibitor (TAE226) 
leading to decreased FAK phosphorylation and cellular 
viability, cell cycle arrest and apoptosis has been 
described in human neuroblastoma cell lines (Beierl t 
al., 2008b). FAK expression was demonstrated in 51 of 
70 clinical neuroblastoma samples by 
immunohistochemistry. FAK protein levels correlated 
with mRNA transcript levels and with advanced 
disease stage in this study (Beierle et al., 2008a). 
Head and neck squamous cell 
carcinoma 
Note 
FAK has been linked to invasion in squamous cell 
carcinoma of the head and neck through promotion of 
cell motility and MMP-2 production (Canel et al., 
2008). FAK gene and protein expression were 
previously evaluated in 211 clinical samples which 
included tissue from cases of dysplasia and benign 
hyperplasia (Canel et al., 2006). In this study, 62% of 
the primary cancers had high FAK protein expression, 
and the levels were consistent with those seen in 
corresponding lymph node metastases. A recent 
preclinial study has implicated FAK phosphorylation 
levels with radioresistance (Hehlgans et al., 2009). 
Thyroid carcinoma 
Note 
Immunohistochemical staining of 108 patient samples 
for FAK protein discriminated malignant from benign 
thyroid lesions. FAK levels correlated with tumor size 
and capsular/lymphatic invasion (Michailidi et al., 
2010). Previously, Kim et al. (2004) reported FAK 
expression in follicular, papillary, medullary and 
anaplastic thyroid carcinomas. FAK was not expressed 
in normal thyroid tissue and nodular hyperplasia, but in 
some of the follicular adenomas included in their study. 
Breast cancer 
Note 
Lahlou et al. (2007) reported a block in tumor 
progression in a transgenic mouse model of breast 
cancer with disrupted FAK function based on Cre/loxP 
recombination. An earlier immunohistochemical study 
on clinical breast tissue showed increased FAK 
expression in ductal carcinoma in situ compared to 
atypical ductal hyperplasia and invasive ductal 
carcinoma (Lightfoot et al., 2004). The authors of this 
study concluded that FAK overexpression precedes 
tumor cell invasion and metastasis. Subsequently, a 
study by Lark et al. (2005) in 629 breast cancer 
samples correlated high FAK protein expression with 
poor prognostic indicators such as high mitotic index 
and nuclear grade, negative hormone receptor status, 
and Her2/neu over-expression. Schmitz et al. (2005) 
provided further evidence to support Her2/neu 
downstream signaling through FAK/Src-mediated 
pathways. Recently, a positive correlation between 
FAK over-expression and p53 mutation status has been
reported (Golubovskaya et al., 2008; Golubovskaya et 
al., 2009). Yom et al. (2010) evaluated 435 cases of 
invasive ductal cancer for FAK gene copy number by 
fluorescence in situ hybridization (FISH) and FAK 
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protein expression by immunohistochemistry, both of 
which correlated with features of aggressive tumor 
biology. Concordance between FISH and 
immunohistochemistry results was observed in 74.9%. 
An increased gene copy number by FISH correlated 
significantly with inferior patient outcome in this study. 
Lung cancer 
Note 
Array comparative genomic hybridization studies on 
clinical samples of small cell lung cancer demonstrated 
regions of copy number alternations (gains and losses) 
enriched for genes involved in focal adhesion signal ng. 
This included gains of FAK copy number which was 
confirmed in a smaller subset of the original 46 cases 
by FISH and quantitative RT-PCR. FAK was also 
highly expressed in tumor tissue (90% of 52 samples) 
in comparison with normal lung samples (Ocak et al., 
2010). Wang et al. (2009) reported results of their study 
focused on FAK expression in bronchio-alveolar 
carcinoma (BAC) and lung adenocarcinomas. They 
found that in lung adenocarcinoma overall survival w s 
better for patients with FAK-negative compared with 
FAK-positive tumors. A study by Hiratsuka et al. 
(2011) implicated endothelial FAK and E-selectin with 
the formation of lung metastasis from distant primay 
tumors due to the formation of discrete foci of vascular 
hyper-permeability important for the initial homing of 
metastatic cancer cells to the lungs. 
Gastro-intestinal tract cancer 
Note 
Giaginis et al. (2009) reported results of an 
immunohistochemical study performed on the two 
major subtypes of gastric adenocarcinoma, including 
30 cases of intestinal- and 36 cases of diffuse-typ. 
Although FAK staining in diffuse-type gastric cancer 
correlated with larger tumor size and advanced disease 
stage, it also correlated with longer overall survival. 
For intestinal type cancer, however, an association with 
increased proliferative capacity and a non-significant 
trend to inferior survival was reported. A retrospective 
study including 444 surgical samples demonstrated a 
positive correlation between FAK gene amplification 
and protein expression levels with tumor size, 
lymphovascular invasion and nodal/distant metastase 
(Park et al., 2010). Focal adhesion kinase protein 
expression and gene amplification were positively 
correlated with each other in this study, and each of 
them was found to be an independent poor prognostic 
factor. 
FAK has been implicated in invasion and metastasis  
well as chemoresistance in pancreatic cancer (Duxbury 
et al., 2003; Duxbury et al., 2004). FAK overexpression 
by immunohistochemistry, demonstrated in 24 of 50 
(48%) patient samples, correlated with tumor size, but 
no other features including grade, lymph node 
involvement or metastasis in a study by Furuyama et al. 
(2006). Another study included an examination of both 
FAK and Src protein levels. FAK expression correlatd 
significantly with tumor stage while Src expression 
correlated with both tumor stage and patient survival, 
and was identified as an independent prognostic factor 
by multivariate analysis (Chatzizacharias et al., 2010). 
Hayashi et al. (2010) demonstrated high levels of 
cytoplasmic FAK expression in normal biliary 
epithelium and observed a gradual loss of staining from 
dysplasia to extra-hepatic bile duct carcinoma. In this
study, positive FAK staining was associated with a 
significantly better survival. Increased levels of FAK 
mRNA and protein have also been observed in a study 
of 60 patients with hepatocellular cancers. Increased 
mRNA levels correlated with tumor size, serum AFP 
and inferior disease-free and overall survival (Fujii et 
al., 2004). 
RNA interference studies in colorectal cancer cell line
xenografts demonstrated that FAK inhibition resulted 
in inhibition of cell proliferation and angiogenesis, 
induction of apoptosis and tumor growth suppression 
(Lei et al., 2010). Elevated levels of FAK mRNA and 
protein were noted in a small cohort of 34 matched 
primary colon cancers and liver metastases (Lark et al., 
2003). More recently a larger series of colorectal 
cancers with matched liver metastases was used to 
evaluate the correlation of FAK staining with clinical 
outcome. In this study, FAK staining was equivalent in 
primary and metastatic lesions, and elevated levels of 
FAK and Src were associated with a reduced time to 
recurrence (de Heer et al., 2008). 
Female genital tract cancer 
Note 
FAK has been implicated in the invasive and metastaic 
phenotype of ovarian cancer through multiple pathways 
(Hu et al., 2008; Yagi et al., 2008). In one report, 
MUC4-induced epithelial-mesenchymal transition was 
partially mediated by FAK, and pharmacologic FAK 
inhibition successfully abrogated MUC4-induced cell 
motility (Ponnusamy et al., 2010). In another study, 
cooperative signaling of c-met and alpha5beta1 integrin 
through FAK/Src was associated with promotion of 
invasion and metastases (Mitra et al., 2010). FAK 
activation also appears to be relevant to the 
development of resistance to standard cytotoxics 
(Halder et al., 2005; Villedieu et al., 2006) and 
preclinical studies have demonstrated therapeutic 
efficacy of various methods of FAK inhibition 
including pharmacologic inhibition and RNA 
interference (Halder et al., 2006; Halder et al., 2007; 
Yang et al., 2007). Sood et al. (2010) recently 
described protection from anoikis by catecholamine 
signaling mediated by FAK. They concluded that these 
results support a role for FAK signaling in the stre s-
mediated promotion of aggressive tumor biology. They 
also demonstrated increased levels of FAK and 
phosphorylated FAK in greater than 50% of the 
examined tumors, both of which correlated with 
inferior patient survival. Two earlier studies 
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documented up-regulation of FAK protein and 
phosphorylated FAK in invasive ovarian cancers in 
comparison with normal epithelium (Sood et al., 2004; 
Grisaru-Granovsky et al., 2005). Sood et al. (2004) also 
noted associations between FAK immunohistochemical 
staining and more advanced tumor stage, tumor grade, 
metastasis and inferior overall survival. 
Immunohistochemical analysis of 134 cases of 
endometrial cancer demonstrated moderate to strong 
staining in the majority (89%) of cases. Weak FAK 
staining was noted in the remaining 11% and associated 
with a trend to improved survival. Increased FAK 
staining, however, correlated with measures of poor 
outcome including tumor grade, lymphovascular 
invasion and lymph node metastases (Gabriel et al., 
2009). A different study demonstrated high levels of 
FAK expression in endometrial cancers of different 
histologies (endometrioid, serous and clear cell) as well 
as in regions of endometrial hyperplasia. The authors 
concluded that their data implicate FAK in endometrial 
carcinogenesis (Livasy et al., 2004). 
An analysis of 166 surgical samples demonstrated 
cytoplasmic and membranous FAK staining in regions 
of cervical dysplasia and frankly invasive cancer of the 
uterine cervix with absent staining in adjacent normal 
cervical epithelium (Gabriel et al., 2006). One third of 
the patients, with tumors exhibiting weak FAK 
staining, had an inferior survival compared to those 
with moderate/strong FAK staining, and weak FAK 
staining correlated with lymph node positivity in this 
study. Oktay et al. (2003) demonstrated positive FAK 
staining in premalignant lesions. Similarly, Schwock et 
al. (2009) demonstrated an increase in FAK expression 
and concurrent decrease of E-cadherin in metastatic 
cervical cancer and carcinoma in-situ compared to 
normal cervical epithelium. An association between E-
cadherin loss and FAK was also noted in an earlier 
study that included 26 carcinomas and 5 carcinoma in 
situ cases (Moon et al., 2003). Although FAK protein 
expression remained constant in this study, elevated 
levels of phosphorylated FAK were found in carcinoma 
samples. 
Male genital tract cancer 
Note 
FAK has been linked with aggressive tumor behavior in 
models of androgen-independent prostate cancer 
(Johnson et al., 2008). An early study comparing 
normal and hyperplastic prostatic tissue with localized 
and advanced prostate cancers demonstrated increased 
levels of total and activated FAK in more advanced 
disease (Tremblay et al., 1996). Association of FAK 
with paxillin and p50csk was noted in cases of 
metastatic cancer. Rovin et al. (2002) described 
increased FAK expression in pre-malignant lesions that
was maintained at different stages of tumor 
progression. A study by Zheng et al. (1999) proposed 
that the migratory behavior of prostate cancer cells is 
related to the de novo expression of alphaVbeta3 
integrin with signaling through FAK. 
Genito-urinary tract cancer 
Note 
Increased levels of FAK and paxillin mRNA transcript 
have been noted in metastasizing renal carcinoma cell 
lines in comparison with normal renal cortex epithel al 
cells (Jenq et al., 1996). FAK/Src signaling was alo 
demonstrated to be relevant to the aggressive behavior 
of bladder carcinoma cells in vitro, and inhibition f the 
phosphatase HD-PTP resulted in an enhanced FAK 




Preclinical studies have implicated FAK with the 
promotion of an aggressive melanoma phenotype 
through its effects on invasion and migration (Hess t 
al., 2005; Hess and Hendrix 2006; Smit et al., 2007; 
Kaneda et al., 2008; Sun et al., 2009). FAK also has 
importance early in the metastatic dissemination of 
melanoma cells (Abdel-Ghany et al., 2002). A study by 
Smith et al. (2005) demonstrated that downregulation 
of FAK by antisense oligonucleotide sensitizes 
melanoma cells to 5-fluorouracil treatment. A 
preliminary clinical report suggests that FAK may 
function as a universal tumor-associated antigen that
could be exploited for cancer immunotherapy including 
melanoma (Kobayashi et al., 2009). A recent study by 
Trimmer et al. (2010) reported reduced levels of 
caveolin-1 in clinical metastases of melanoma as well 
as in highly metastatic melanoma cell lines. They 
demonstrated that caveolin-1 expression in B16F10 
melanoma cells promotes cell proliferation while 
suppressing invasion and migration via FAK/Src.  
McLean et al. (2004) demonstrated a role for FAK in 
the malignant progression from papilloma to squamous 
cell carcinoma in a transgenic mouse model combined 
with chemical carcinogenesis. No effect of the FAK 
deletion was noted on wound re-epithelialization. 
Soft tissues, bone and hemato-
lymphoid tissues 
Note 
Yui et al. (2010) developed a highly metastatic 
osteosarcoma cell line through in vivo selection which, 
in comparison with the parental line, demonstrated 
higher levels of activated FAK and cdc42. Hanada et 
al. (2005) showed localization of phosphorylated FAK 
at the infiltrative edge in a three dimensional culture 
model using invasive murine fibrosarcoma cells. In the 
same study, expression of FAK-related non-kinase 
(FRNK) inhibited experimental metastases in syngenic 
mice without significant effects on primary tumor 
growth. In a study on bone metastasis, the dual 
FAK/Pyk2 inhibitor PF-271 suppressed the growth of 
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experimental intra-tibial tumors in rats and restored 
tumor-induced bone loss (Bagi et al., 2008). 
Immunohistochemical analysis of normal and 
neoplastic hemato-lymphoid tissues demonstrated FAK
staining in B cells of the germinal center, marginal and 
mantle zones (Ozkal et al., 2009). Corresponding 
staining was present in most B-cell lymphomas while 
T-cell lymphomas were predominantly negative. 
Neoplastic cells of classical Hodgkin's lymphoma were 
negative for FAK while those of lymphocyte-
predominant Hodgkin's lymphoma were positive in the 
same study. 
A study of 60 primary acute myeloid leukemia samples 
demonstrated FAK transcript and protein expression in 
48% cases and Pyk2 expression in 81% cases (Recher 
et al., 2004). FAK-positive acute myeloid leukemia 
cells displayed a higher migratory efficiency and lower 
sensitivity to chemotherapy. FAK expression positively 
correlated with white blood count at diagnosis, death 
rate and median survival. 
Non-neoplastic disorders 
Note 
Shahrara et al. (2007) reported on the elevated 
expression of phosphorylated FAK, Pyk2 and other 
signaling molecules, in synovial tissues of patients with 
rheumatoid or osteoarthritis. They postulated that FAK 
signaling may be important for the recruitment of 
inflammatory cells into susceptible joints and required 
to promote the disease process.  
Chen et al. (2001) found that keratinocytes from 
patients with psoriasis have elevated levels of 
phosphorylated FAK and concluded that integrin/FAK 
signaling contributes to a 'pre-activation' of uninvolved 
keratinocytes that predisposes to the development of 
psoriatic plaques in response to certain stimuli. 
FAK has a role in the development of the 
cardiovascular system since FAK-null mice are 
embryonically lethal with phenotypic abnormalities 
approximating those seen in human congenital heart 
defects (Vadali et al., 2007). FAK also appears to be 
involved cardiac hypertrophy and heart failure through 
its involvement in the cardiac response to biochemical 
stress and hypertrophic agonists. The relevance of FAK 
to cardiac physiology likely differs with the cellular 
context. Although FAK activation has been suggested 
to accelerate function deterioration of an overloaded 
heart, selective FAK deletion in cardiomyoctes has also 
been associated with maladaptive cardiac remodeling 
(Franchini et al., 2009). 
FAK appears to be essential for normal glucose 
transport and glycogen synthesis due to cross talk 
between integrin and insulin signaling pathways 
(Huang et al., 2002; Huang et al., 2006). FAK has also
been implicated in hyperglycemia-related vascular 
complications in Diabetes mellitus (Mori et al., 200 ). 
Two independent studies reported on increased levels  
of activated FAK in the glomeruli from diabetic rats 
that could be abrogated by insulin treatment (Clark et 
al., 1995; Shikano et al., 1996).  
FAK signaling has been implicated with non-neoplastic 
renal disease. Holzapfel et al. (2007) documented a role 
for FAK during restoration of tubular integrity in renal 
ischemia and reperfusion, and an earlier study by 
Morino et al. (1999) indicated activated FAK-signali g 
during the development and progression of 
autoimmune-mediated nephritis in an animal model. 
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